ArticleNeurobiology of aging2015
Suspected non-AD pathology in mild cognitive impairment.
Article in Neurobiology of aging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis.Alzheimer's research & therapy · 2024Pooled it
- 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).The Cochrane database of systematic reviews · 2017Pooled it
- Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study.Scientific reports · 2017Trial
- Differential atrophy along the longitudinal axis of the hippocampus in Alzheimer's disease and suspected non-Alzheimer's disease pathophysiology (SNAP).Neuroradiology · 2026Article
- Astrocyte reactivity across the AD continuum measured by [European journal of nuclear medicine and molecular imaging · 2026Article
- A dual space MRI radiomic network signature for risk stratification and subtyping of mild cognitive impairment.iScience · 2026Article
- Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.bioRxiv : the preprint server for biology · 2026Article
- Decoupling MCI-specific signatures from shared neurobiological substrates of cognitive aging via deep learning.NPJ digital medicine · 2026Article
- Differences in cognitive performance and neuroanatomy according to Alzheimer's disease pathophysiology.Arquivos de neuro-psiquiatria · 2026Article
- Role of the Clock Drawing Test in Differential Diagnosis of Alzheimer's Disease: Clinical Findings in Relation to CSF Biomarkers.International journal of molecular sciences · 2026Article
- Alzheimer mimicry: LATE and PART.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Distinct Characteristics of Suspected Non-Alzheimer Pathophysiology in Relation to Cognitive Status and Cerebrovascular Burden.Clinical nuclear medicine · 2025Article
- The clinical importance of suspected non-Alzheimer disease pathophysiology.Nature reviews. Neurology · 2024Review
- Clinical variables contributing to the identification of biologically defined subgroups within cognitively unimpaired and mild cognitive impairment individuals.European journal of neurology · 2024Article
- DNALI1 Promotes Neurodegeneration after Traumatic Brain Injury via Inhibition of Autophagosome-Lysosome Fusion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Distinct subtypes of spatial brain metabolism patterns in Alzheimer's disease identified by deep learning-based FDG PET clusters.European journal of nuclear medicine and molecular imaging · 2024Article
- Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology.Journal of Alzheimer's disease : JAD · 2024Article
- ATN Classification and Clinical Progression of the Amyloid-Negative Group in Alzheimer's Disease Neuroimaging Initiative Participants.Chonnam medical journal · 2024Article
- Could Temperamental Features Modulate Participation in Clinical Trials?Journal of clinical medicine · 2023Article
- Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer's Disease Continuum.Journal of Alzheimer's disease : JAD · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.